Indication: Used to treat symptoms of menopause, deficiencies in ovary function (including underdevelopment of female sexual characteristics and some types of infertility), and in rare cases, prostate cancer. Chlorotrianisene may also be used to prevent breast engorgement following childbirth.
Pharmacology: Chlorotrianisene is a nonsteroidal synthetic estrogen. After menopause, when the body no longer produces estrogen, chlorotrianisene is used as a simple replacement of estrogen. The estrogen-stimulated endometrium may bleed within 48-72 hours after discontinuance of estrogen therapy. Paradoxically, prolonged estrogen therapy may cause shrinkage of the endometrium and an increase in size of the myometrium. Estrogens have a weak anabolic effect and may cause sodium retention with associated fluid retention and edema. Estrogens may also decrease elevated blood cholesterol and phospholipid concentrations. Estrogens affect bone by increasing calcium deposition and accelerating epiphyseal closure, following initial growth stimulation. During the preovulatory or nonovulatory phase of the menstrual cycle, estrogen is the principal determinant in the onset of menstruation. A decline of estrogenic activity at the end of the menstrual cycle also may induce menstruation; however, the cessation of progesterone secretion is the most important factor during the mature ovulatory phase of the menstrual cycle. The benefit derived from estrogen therapy in the prevention of postpartum breast engorgement must be carefully weighed against the potential increased risk of puerperal thromboembolism associated with the use of large doses of estrogens.
Mechanism Of Action: Chlorotrianisene binds to the estrogen receptor on various estrogen receptor bearing cells. Target cells include cells in the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.
Drug Category: Antineoplastic Agents; Estrogens, Non-Steroidal; ATC:G03CA06
Absorption: Absorption following oral administration is rapid.
Interactions:
DrugBank: Interactions for Chlorotrianisene
Interactions for Chlorotrianisene:
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates,
bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin,
tamoxifen, and warfarin.
Chemical IUPAC Name: 1-[2-chloro-1,2-bis(4-methoxyphenyl)-ethenyl]-4-methoxy-benzene
Chemical Formula: C23H21ClO3
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00715
CAS Registry Number: 569-57-3
Chlorotrianisene News (When available)
ABORTED: Photos Of New Lineup Posted Online - Jan. 16, 200616 Jan 2006 Blabbermouth.net, Purulator (ex-GARWALL, BALROG, GENITAL GRINDER) on guitar and Olivia Scemama (ex-NO RETURN, BALROG) on bass following the departures of Thijs "Tace" de Cloedt ...
Aborted part ways with guitarist and bassistJan 2, 2006 The Gauntlet, Aborted have posted the following on their official website regarding the dismissals of Tace and Frederic. "Due to personal issues ...
ABORTED Part Ways With Guitarist, Bassist - Jan. 2, 2006Jan 2, 2006 Blabbermouth.net, Belgian death metallers ABORTED have parted ways with guitarist Thijs "Tace" de Cloedt and bassist Frederic "Free" Vanmassenhove due to "personal issues." "A ...
SciClone Reports Results From ZADAXIN Proof-of-Concept Liver ...Dec 21, 2005 Market Wire (press release) ...trial indicating a trend toward positive survival benefit in patients treated with ZADAXIN® plus trans arterial chemo-embolization (TACE) compared with ...
News tips from the Journal of NeuroscienceJan 4, 2006 EurekAlert (press release), The authors report that TACE, the tumor necrosis factor-á converting enzyme, is required for the TGFá–erB1 signaling in hypothalamic astrocytes. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
